Xintela AB (publ) (STO:XINT)

Market Cap	245.46M -33.6%
Revenue (ttm)	2.28M -45.9%
Net Income	-48.56M
EPS	-0.07
Shares Out	861.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,008
Average Volume	273,346
Open	0.2830
Previous Close	0.2850
Day's Range	0.2630 - 0.2850
52-Week Range	0.2100 - 0.5800
Beta	2.14
RSI	63.37
Earnings Date	May 22, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XINT

Financial Performance

In 2025, Xintela AB's revenue was 2.28 million, a decrease of -45.86% compared to the previous year's 4.22 million. Losses were -48.56 million, 23.9% more than in 2024.